期刊文献+

慢性丙型肝炎个体化治疗研究进展 被引量:4

Research progress on individualized treatment of chronic hepatitis C
下载PDF
导出
摘要 丙型肝炎是由丙型肝炎病毒(HCV)引起的急、慢性传染病。丙型肝炎流行广泛,慢性化率高达50%~85%,并可转化为肝硬化和肝细胞肝癌。目前慢性丙型肝炎(CHC)的标准治疗方案为聚乙二醇干扰素联合利巴韦林,但约50%的HCV 1型感染者不能获得持续病毒学应答。研究发现,HCV基因型、病毒载量,以及宿主的性别、年龄、乙醇摄入量、肝纤维化程度、合并感染、基因多态性等因素可影响治疗效果。其中,HCV病毒载量、HCV基因型及宿主基因多态性是预测持续病毒学应答的重要因素,可用于制订个体化治疗方案。 Hepatitis C, caused by infection of hepatitis disease involved with a significant proportion of the C virus (HCV), is an acute and/or chronic infectious worldwide population. In general, 50%-85% of the infections might become chronic hepatitis C or carriers, thereafter developing into cirrhosis and hepatocellular carcinoma. Currently, the standard care for chronic hepatitis C is pegylated interferon a (PEG-INFa) plus ribavirin (RBV). Nevertheless, about 50% of the patients infected with HCV genotype 1 fail to achieve sustained virological response (SVR) although they share the same or similar diagnosis. A number of clinical studies show that the efficacy of standard care depends on both virus and host factors. The predictors of SVR on the HCV side include viral load and genotype; on the host side, gender, age, alcohol consumption, fibrosis stage, co-infection with other viruses, and genetic polymorphisms are included. Among those, the most important elements that may play significant roles in the individualized treatment of HCV infections are the viral load and genotype as well as the variation in the host gene interleukin 28B (IL-28B).
出处 《微生物与感染》 2013年第3期186-191,共6页 Journal of Microbes and Infections
关键词 慢性丙型肝炎 病毒载量 基因型 宿主基因多态性 个体化治疗 Chronic hepatitis C Viral load Genotype Host genetic polymorphism Individualized treatment
  • 相关文献

参考文献31

  • 1Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection[J]. Lancet Infect Dis, 2005, 5 (9) : 558-567.
  • 2丙型肝炎防治指南[J].中华内科杂志,2004,43(7):551-555. 被引量:106
  • 3European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection [J]. J Hepatol, 2011, 55 (2):245-264.
  • 4Ge D, Fellay J, Thompson A3, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance [J]. Nature, 2009, 461 (7262):399-401.
  • 5Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dote GJ, Powell E, Riordan S,Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy [J]. Nat Genet, 2009,41 (10) :1100-1104.
  • 6Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K. Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, lto Y, Mita E, Tanaka E, Mochida S, Murawaki Y, ttonda M. Sakai A. ttiasa Y. Nishiguchi S, Koike A,Sakaida I, Imamura M, lto K, Yano K, Masaki N,Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon- alpha and ribavirin therapy for chronic hepatitis C [J].Nat Genet, 2009, 41 (10): 1105-1109.
  • 7Thomas DE., Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM,Rosen HR, Tobler EH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IE28B and spontaneous clearance of hepatitis C virus [J]. Nature, 2009, 461 (7265):798-801.
  • 8高晓娟,余祖江,刘翠萍.白细胞介素-28B的基因多态性与干扰素抗丙型肝炎病毒治疗应答的关系[J].第三军医大学学报,2012,34(9):832-835. 被引量:5
  • 9徐辉,郭丽琳,何伶俐,陈杨,刘凯,雷秉钧,雷学忠.宿主白介素28B基因多态性与慢性丙型肝炎抗病毒疗效的研究分析[J].四川大学学报(医学版),2012,43(6):855-859. 被引量:6
  • 10陶剑,刘俊,雷华,普冬.丙型肝炎患者IL28B基因型和HCV基因型对抗病毒治疗的影响[J].世界华人消化杂志,2011,19(22):2372-2375. 被引量:4

二级参考文献63

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 2任芙蓉,庄辉.丙型肝炎病毒抗体酶联免疫试验S/CO比值与补充试验阳性的相关性研究进展[J].中华检验医学杂志,2005,28(10):1096-1099. 被引量:17
  • 3Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374.
  • 4Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 2004; 85: 3173-3188.
  • 5Germer JJ, Majewski DW, Yung B, Mitchell PS, Yao JD. Evaluation of the invader assay for genotyping hepatitis C virus. J Clin Microbio12006; 44:318-323.
  • 6Zeuzem S, Yoshida EM, Benhamou Y, Pianko S, Bain VG, Shouval D, FIisiak R, Rehak V, Grigorescu M, Kaita K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype I chronic hepatitis C. Hepatology 2008; 48:407-417.
  • 7Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, Vinelli F, Scot-to G, Montalto G, Romano M, Cristofaro G, Mottola L, Spirito F, Andriulli A. Individualized treatment duration for hepatitis C genotype I patients: A randomized controlled trial. Hepatology 2008; 47:43-50.
  • 8Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100-1104.
  • 9Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
  • 10Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance. Nature 2009; 461: 399-401.

共引文献140

同被引文献35

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部